← Sam Fazeli

What podcasts say about Sam Fazeli

Every statement, with the speaker, the exact quote and the moment it was said.

What Sam Fazeli has said on podcasts

19 statements · 12 positive · 6 negative · 1 mixed

  1. on AI data gatheringPositiveOct 30, 2026· Biotech Hangout

    AI can replace two or three contractors for some data-gathering tasks.

    “i can displace two or three contractors, for instance, in some data gathering”

    Listen at 14:48

    Open the episode · Episode 201 - October 30, 2026
  2. on Human oversight of AI dataNegativeOct 30, 2026· Biotech Hangout

    Human review remains necessary to finalize AI-gathered data quality.

    “I still need the human in the loop to finalize the quality of the data”

    Listen at 14:56

    Open the episode · Episode 201 - October 30, 2026
  3. on Iran-related geopolitical attackNegativeOct 30, 2026· Biotech Hangout

    A major Iran-related attack could raise oil prices and interest rates.

    “a massive jump in oil prices could result in higher interest rates”

    Listen at 28:14

    Open the episode · Episode 201 - October 30, 2026
  4. on Interest rates and biotechNegativeOct 30, 2026· Biotech Hangout

    Higher interest rates negatively affect biotech markets.

    “interest rates, which we would love to believe that are not related, are not impacting biotech. But I think they do if they go high enough.”

    Listen at 28:41

    Open the episode · Episode 201 - October 30, 2026
  5. on AmgenPositiveOct 30, 2026· Biotech Hangout

    Amgen’s Delphi 305 data appeared practice-changing in small-cell lung cancer.

    “I did see at least that as a practice-changing data set.”

    Listen at 43:21

    Open the episode · Episode 201 - October 30, 2026
  6. on AmgenPositiveOct 30, 2026· Biotech Hangout

    Delphi 305 is likely to change small-cell lung-cancer standard of care.

    “this is standard of care changing.”

    Listen at 49:45

    Open the episode · Episode 201 - October 30, 2026
  7. on AmgenPositiveOct 30, 2026· Biotech Hangout

    Delphi 312 is expected to succeed after Delphi 305.

    “I'm pretty convinced will be successful too”

    Listen at 50:01

    Open the episode · Episode 201 - October 30, 2026
  8. on Ivanezumab first-line biliary-tract cancer trialPositiveOct 30, 2026· Biotech Hangout

    Ivanezumab improved overall and progression-free survival versus control.

    “This hit both on overall survival and on progression-free survival.”

    Listen at 52:30

    Open the episode · Episode 201 - October 30, 2026
  9. on Moderna cancer vaccineMixedOct 23, 2026· Biotech Hangout

    Moderna’s valuation reflected substantial market expectations for its cancer vaccine.

    “we're sitting here with revenue of what 2.2 2.3 billion dollars this year and therefore the amount of hope that's been pumped into this um story by the market um for the cancer vaccine is incredible”

    Listen at 6:42

    Open the episode · Episode 200 - October 23, 2026
  10. on Moderna cancer vaccinePositiveOct 23, 2026· Biotech Hangout

    Market expectations for Moderna’s cancer vaccine became exceptionally high.

    “the amount of hope that's been pumped into this um story by the market um for the cancer vaccine is incredible”

    Listen at 6:48

    Open the episode · Episode 200 - October 23, 2026
  11. on ModernaNegativeOct 23, 2026· Biotech Hangout

    Moderna’s valuation had reached a level requiring nearly perfect results.

    “it was getting to a point where you needed absolute perfection”

    Listen at 7:40

    Open the episode · Episode 200 - October 23, 2026
  12. on Moderna valuationNegativeOct 23, 2026· Biotech Hangout

    Moderna’s valuation had reached a level requiring near-perfect execution.

    “you needed absolute perfection”

    Listen at 7:41

    Open the episode · Episode 200 - October 23, 2026
  13. on ModernaNegativeOct 23, 2026· Biotech Hangout

    Investors were seeking reasons to take profits after Moderna’s large increase.

    “all that's going on here is people have tried to find a reason to to take profit for something that's gone up i don't know 200 300 400 depending where you measure it from”

    Listen at 9:29

    Open the episode · Episode 200 - October 23, 2026
  14. on biotech sector fundamentalsPositiveOct 23, 2026· Biotech Hangout

    Biotech sector fundamentals are exceptionally strong.

    “The fundamentals of the sector are phenomenal.”

    Listen at 24:41

    Open the episode · Episode 200 - October 23, 2026
  15. on biotech sector fundamentalsPositiveOct 23, 2026· Biotech Hangout

    Biotech sector fundamentals are exceptionally strong despite external volatility.

    “The fundamentals of the sector are phenomenal”

    Listen at 24:41

    Open the episode · Episode 200 - October 23, 2026
  16. on oncologyPositiveOct 23, 2026· Biotech Hangout

    Oncology will make substantial progress against difficult diseases, including GBM.

    “i think that oncology would be again solving the diseases that they are difficult gbm potentially some of the smaller indications i think we'll see a lot of progress there”

    Listen at 56:14

    Open the episode · Episode 200 - October 23, 2026
  17. on oncologyPositiveOct 23, 2026· Biotech Hangout

    Oncology will make substantial progress against difficult diseases including GBM and smaller indications.

    “oncology would be again solving the diseases that they are difficult gbm potentially some of the smaller indications”

    Listen at 56:15

    Open the episode · Episode 200 - October 23, 2026
  18. on cancer treatmentPositiveOct 23, 2026· Biotech Hangout

    Cancer treatment will increasingly enable patients to live with cancer rather than die from it.

    “a lot of people living with cancer as opposed to dying of it”

    Listen at 56:26

    Open the episode · Episode 200 - October 23, 2026
  19. on neurological diseasesPositiveOct 23, 2026· Biotech Hangout

    Neurological diseases will eventually become treatable through major neuroscience advances.

    “neuroscience i'm really looking forward to neurological diseases being finally cracked open and treated”

    Listen at 56:30

    Open the episode · Episode 200 - October 23, 2026

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.